Jia Qiutian, Deng Yulin, Qing Hong
School of Life Science, Beijing Institute of Technology, 5 South Zhongguancun Street, Haidian District, Beijing 100081, China.
Biomed Res Int. 2014;2014:837157. doi: 10.1155/2014/837157. Epub 2014 Jul 17.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with two hallmarks: β-amyloid plagues and neurofibrillary tangles. It is one of the most alarming illnesses to elderly people. No effective drugs and therapies have been developed, while mechanism-based explorations of therapeutic approaches have been intensively investigated. Outcomes of clinical trials suggested several pitfalls in the choice of biomarkers, development of drug candidates, and interaction of drug-targeted molecules; however, they also aroused concerns on the potential deficiency in our understanding of pathogenesis of AD, and ultimately stimulated the advent of novel drug targets tests. The anticipated increase of AD patients in next few decades makes development of better therapy an urgent issue. Here we attempt to summarize and compare putative therapeutic strategies that have completed clinical trials or are currently being tested from various perspectives to provide insights for treatments of Alzheimer's disease.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,具有两个特征:β淀粉样蛋白斑块和神经原纤维缠结。它是老年人最令人担忧的疾病之一。目前尚未开发出有效的药物和疗法,而基于机制的治疗方法探索一直在深入研究。临床试验结果表明,在生物标志物的选择、候选药物的开发以及药物靶向分子的相互作用方面存在几个陷阱;然而,这些结果也引发了人们对我们对AD发病机制理解可能存在不足的担忧,并最终刺激了新型药物靶点测试的出现。预计在未来几十年AD患者数量会增加,因此开发更好的治疗方法成为一个紧迫的问题。在这里,我们试图从各个角度总结和比较已完成临床试验或目前正在测试的假定治疗策略,为阿尔茨海默病的治疗提供见解。